Vertex Announces European Medicines Agency Type II Variation Marketing Authorization Application Validation for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination with ivacaftor in People with One Copy of the F508del Mutation

Vertex announces validation of licence extension application by European Medicines Agency for Kaftrio® (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor in people with one copy of the F508del Mutation

Biospace Inc.